FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1034-1035 September 2, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Langerhans'-cell histiocytosis (LCH) is a rare disorder characterized by tissue infiltrates of CD1a+ Langerhans' cells, eosinophils, neutrophils, macrophages, and lymphocytes. Systemic treatments for refractory LCH are unsatisfactory and usually toxic. We report the use of imatinib mesylate to control parenchymal brain involvement in a patient with multisystem LCH.

A 37-year-old woman was hospitalized because of severe headache and visual impairment after fainting. She had a 14-year-history of LCH, with involvement of bone and lungs, and diabetes insipidus and had previously been treated with thymic peptides, chemotherapy, and radiotherapy of the occipital bone. Neurologic examination revealed mydriasis, slow . . . [Full Text of this Article]

This article has been cited by other articles:

• Haroche, J., Amoura, Z., Charlotte, F., Salvatierra, J., Wechsler, B., Graux, C., Brousse, N., Piette, J.-C. (2008). Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111: 5413-5415 [Full Text]  
• von Stebut, E., Schadmand-Fischer, S., Brauninger, W., Kreft, A., Doberauer, C., Steinbrink, K. (2008). Successful Treatment of Adult Multisystemic Langerhans Cell Histiocytosis With Psoralen-UV-A, Prednisolone, Mercaptopurine, and Vinblastine. Arch Dermatol 144: 649-653 [Abstract] [Full Text]  
• Utikal, J., Ugurel, S., Kurzen, H., Erben, P., Reiter, A., Hochhaus, A., Nebe, T., Hildenbrand, R., Haberkorn, U., Goerdt, S., Schadendorf, D. (2007). Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. Arch Dermatol 143: 736-740 [Abstract] [Full Text]  
• Montella, L., Palmieri, G., Lacouture, M. (2007). The Era of Targeted Therapies: Increasing Role for Novel Oncologic Drugs in Dermatology. Arch Dermatol 143: 788-789 [Full Text]  
• Brown, R. E. (2005). Morphoproteomic Analysis of Osteolytic Langerhans Cell Histiocytosis with Therapeutic Implications. Annals of Clinical & Laboratory Science 35: 131-136 [Abstract] [Full Text]